Physician profile
Jean Brown
NPI 1932179520
$1,921.77
in general payments reported to CMS, 2019-2025
22 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $368 · 2023: $607 · 2024: $509 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $338.14 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $310.65 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $290.90 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.73 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $92.93 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $91.42 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $90.21 | 2021-2024 | |
| Pfizer INC. | $68.60 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $65.78 | 2023-2024 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $61.12 | 2021-2023 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $40.23 | 2023-2024 | Rexulti, Abilify Maintena |
| Renalytix Ai, INC. | $33.79 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Biohaven Pharmaceuticals, INC. | $29.60 | 2021 | |
| Idorsia Pharmaceuticals US INC | $23.00 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $21.65 | 2023 | Gvoke Hypopen |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $19.68 | 2022 | |
| Amgen INC. | $18.50 | 2023 | Otezla, Repatha |
| Currax Pharmaceuticals LLC | $17.99 | 2025 | Contrave |
| Horizon Therapeutics Plc | $17.59 | 2022 | |
| Axsome Therapeutics, INC. | $14.81 | 2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $14.20 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.25 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.